In addition, part of the CML patients do not respond to imatinib or second- or third-generation TKIs.16 Therefore, the discovery of novel signaling pathways associated with BCR–ABL1-induced tumorigenesis is still a matter of importance for patients with BCR–ABL1-positive leukemia. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.